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Background
Previous studies examining barriers and willingness to par-
ticipate in HIV vaccine trials have demonstrated the role
of factors identified by the Health Belief Model. Barriers to
cancer trials can also be understood in terms of a theoreti-
cal framework consisting of the locus of the barrier (perso-
nal vs. social) and the nature of the barrier (risk vs. cost).
In this systematic review of review articles, we extend this
framework to another life-threatening disease, cancer. The
purpose is to improve conceptual clarity about volunteer-
ing in clinical trials by comparing and contrasting barriers
in these two areas.
Methods
In 2012, two people independently searched the Cochrane
Database for Systematic Reviews, Pubmed, Embase, and
Google Scholar to identify review articles examining can-
cer trial barriers to participation. Search terms used were:
“cancer”, “oncology”, “cancer trials”, “oncology trials”,
“clinical trials”, “medical research”, “willingness to partici-
pate”, “barriers”. Review articles were also retrieved from
our search examining motivators to participation in cancer
research and from bibliographic references.
Results
We retrieved 19 review articles from 2000-2012 examining
barriers to participation in cancer trials. “Reduced quality
of life” / “distrust of institutions” / “loss of control” were
personal risks (PR). “Perceptions of the provider” / “subjec-
tive norms” were social risks (SR). “Side effects” / “experi-
mental nature of the trial” were personal costs (PC).
Misconceptions included “confidentiality concerns”. Con-
sistent with HIV vaccine trials, most barriers with regards
to cancer trials were related to PR and PC. More
misconceptions were identified in HIV vaccine prepared-
ness studies (VPS).
Conclusion
Personal risk, PC, and SR barriers were similar to those
identified in HIV VPS, but more misconceptions were
identified in the latter. Understanding barriers can result
in better recommendations on how to overcome these
barriers. A limitation is that cancer populations are differ-
ent than those affected by HIV.
Author details
1University of British Columbia, Vancouver, Canada. 2School of Population
and Public Health, University of British Columbia, Vancouver, Canada.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-P109
Cite this article as: Dhalla and Poole: Barriers to participation in HIV
vaccine trials and cancer trials: a cost-gain analysis. Retrovirology 2012
9(Suppl 2):P109.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1University of British Columbia, Vancouver, Canada
Full list of author information is available at the end of the article
Dhalla and Poole Retrovirology 2012, 9(Suppl 2):P109
http://www.retrovirology.com/content/9/S2/P109
© 2012 Dhalla and Poole; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
